Pronzato P, Ardizzoni A, Conte P F, Gulisano M, Lionetto R, Repetto L, Scornavacche V, Sertoli M R, Rosso R
Chemioterapia. 1986 Jun;5(3):150-3.
A phase II study with mitoxantrone has been carried out in 30 metastatic breast cancer patients. Of 26 evaluable patients 7 (26.9%) experienced a partial response; 7 (26.9%) patients had stable disease and 12 (46.1%) had progression. Major toxicity observed was: nausea and vomiting in 52% of patients, moderate hair loss in 53% of patients and leukopenia in 53%.
一项针对米托蒽醌的II期研究在30例转移性乳腺癌患者中开展。在26例可评估患者中，7例（26.9%）出现部分缓解；7例（26.9%）患者病情稳定，12例（46.1%）病情进展。观察到的主要毒性反应为：52%的患者出现恶心和呕吐，53%的患者出现中度脱发，53%的患者出现白细胞减少。
